Products

Eisai Group will promote creating solutions (new drugs) based on scientific evidence in the areas of its expertise: neurology and oncology.

In addition, Eisai is committed to maximizing value for patients by developing additional formulations and expanding indications of our global brands: Halaven®, Lenvima®,  Fycompa® and Dayvigo®.

In the neurology area, our in-house discovered and developed antiepileptic drug Fycompa® is approved as an adjunctive therapy for partial-onset seizures in over 70 countries including Japan, the United States, China and other countries in Europe and in Asia. It is also approved for use as a monotherapy and for adjunctive use in the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in Japan, the United States and China. In addition, Fycompa is approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, in Europe and in Asia. The insomnia treatment Dayvigo® has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.

In the oncology area, our in-house discovered and developed anticancer agent Halaven has been approved for use in the treatment of breast cancer in over 80 countries and also for use in the treatment of malignant soft tissue sarcoma in over 80 countries. Lenvima, another anticancer agent discovered and developed in-house, has been approved for use in the treatment of thyroid cancer in over 80 countries, including Japan, the United States, in Europe, and in Asia. Lenvima has also been approved for use in the treatment of hepatocellular carcinoma in over 75 countries including in Japan, the United States, China and other countries in Europe and in Asia. It has also been approved for use in the treatment of thymic carcinoma in Japan. It has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in over 60 countries including the United States and Europe. Finally, Lenvima has been approved for use in the treatment of endometrial carcinoma in combination with pembrolizumab in over 45 countries including in Japan, the United States, and countries in Europe and in Asia. In addition, it has been approved for use in the treatment of renal cell carcinoma in combination with pembrolizumab in over 35 countries including in Japan, the United States, and countries in Europe and in Asia. (In Europe, the product name for this indication is Kisplyx®.)

(Information current as of May 2022)

(Information current as of May 2022)

(Information current as of May 2022)